All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec006}
============

Infective endocarditis (IE) is an uncommon infectious disease but with significant mortality and morbidity \[[@pone.0225077.ref001]\]. The mortality rate of infective endocarditis is 25% \[[@pone.0225077.ref001]\]. In most population surveys, its incidence ranges from 3--7 per 100,000 people per year \[[@pone.0225077.ref002]\]. Infective endocarditis ranks fourth among the life-threatening infections. In 2010, it was estimated that IE causes 1.58 million disability-adjusted life-years worldwide \[[@pone.0225077.ref003]\]. The causative organism isolated is *Viridans streptococci* in 35--45% of the patients \[[@pone.0225077.ref004]\]. According to a survey in France, the microbiological profile of infective endocarditis has changed in recent years \[[@pone.0225077.ref005]\]. *Staphylococcus aureus* causes the majority of the cases of infective endocarditis in the industrialized world. There is a higher incidence of infective endocarditis in older age, those with prosthetic heart valves and cardiac devices while at the same time, there is a decreased proportion of IE in rheumatic heart disease \[[@pone.0225077.ref006]\].

Infective endocarditis presents with high-grade fever, valvulitis, peripheral emboli, immunological phenomenon and sustained bacteremia or fungemia. However, the typical history and clinical manifestations are not present in most of the patients. So, the diagnosis of infective endocarditis relies on a highly sensitive and specific diagnostic strategy. In 1994, a diagnostic scheme was formulated in Duke University Medical Center. According to this scheme, patients with suspected infective endocarditis were allocated into three classes: definite, possible and rejected cases([Table 1](#pone.0225077.t001){ref-type="table"}) \[[@pone.0225077.ref007]\].

10.1371/journal.pone.0225077.t001

###### Definitions of definite, possible and rejected infective endocarditis \[[@pone.0225077.ref007]\].

![](pone.0225077.t001){#pone.0225077.t001g}

  ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Definite IE**         **Pathological criteria**                                                                                                                                                                                                                                            Microorganisms demonstrated by culture or histological examination of vegetation, vegetation that has embolized, or an intracardiac abscess specimen; or pathological lesions; vegetation or intracardiac abscess confirmed by histological examination showing active endocarditis
  **Clinical criteria**   2 Major criteria, 1 major criterion and 3 minor criteria, or 5 minor criteria                                                                                                                                                                                        
  **Possible IE**         1 Major criterion and 1 minor criterion, or 3 minor criteria                                                                                                                                                                                                         
  **Rejected**            Firm alterative diagnosis explaining evidence of IE; or resolution of IE syndrome with antibiotic therapy for ≤ 4 d; or no pathological evidence of IE at surgery or autopsy with antibiotic therapy for ≤ 4 d; or does not meet criteria for possible IE as above   
  ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Antibiotic prophylaxis is given for the prevention of infective endocarditis in high-risk persons before dental treatment \[[@pone.0225077.ref008]\]. The high-risk persons for infective endocarditis include those withtheprevious episode of infective endocarditis, congenital heart defects and prosthetic heart valves. Individuals with the history of rheumatic fever, heart murmur and native valve disease are at moderate risk of infective endocarditis\[[@pone.0225077.ref004]\].

Aortic stenosis is the most prevalent valvular abnormality in adults with a higherincidencein advanced age. The frequency of aortic stenosis has increased due to increasing life expectancies\[[@pone.0225077.ref009]\]. The patients with aortic stenosis are treated with conventional cardiac surgery, surgical aortic valve replacement (SAVR). Until recently due to significant mortality associated with SAVR, elderly patients with co-morbidities were not treated\[[@pone.0225077.ref010]\].

Transcatheter aortic valve implantation (TAVI) was introduced in 2006 as a revolutionary intervention for severe aortic stenosis. It is a less invasive procedure for high-risk patients or patients who are inoperable by SAVR\[[@pone.0225077.ref011], [@pone.0225077.ref012]\].Sternotomy is not required in TAVI. A bioprosthetic valve is implanted over the native valve using a catheter. The mortality rate after TAVI is reported to be 14%-31% after 1 year\[[@pone.0225077.ref013]\]. The commonly used TAVI systems are the Edwards SAPIEN valve and the CoreValve®. Both of them are effective and safe\[[@pone.0225077.ref014]\]. Transcatheter aortic valve implantation can be performed through various approaches such as transfemoral, transapical, subclavian or direct aortic approach. The transfemoral approach is done in 80--90% of the cases and is appropriate for both types of the valve\[[@pone.0225077.ref015]\]. The success rate after TAVI is more than 90% and 30-day procedural mortality rates less than 10%\[[@pone.0225077.ref016]\]. The majority of the complications after TAVI are technical and device-related including conduction disturbances and periprosthetic paravalvular leaks\[[@pone.0225077.ref017]\].After the success of TAVI in aortic stenosis, several strategies have been established to treat aortic regurgitation with TAVI \[[@pone.0225077.ref018]\].

Infective endocarditis (IE) is a fatal complication of TAVI\[[@pone.0225077.ref019]\]. The incidence of infective endocarditis after TAVI is low, although it is a major cause of heart failure. As TAVI is becoming more popular with time, the magnitude of post-TAVI infective endocarditis will rise\[[@pone.0225077.ref020]\]. The patients with post-TAVI infective endocarditis have an atypical clinical presentation causing a delay its diagnosis and treatment\[[@pone.0225077.ref021]\].Surgical aortic valve replacement is often required to explant the valve with endocarditis and most of these patients are inoperable or at high risk for SAVR\[[@pone.0225077.ref012]\]. The majority of the patients who underwent TAVI are elderly and infective endocarditis could have the worst prognosis in them\[[@pone.0225077.ref022]\].The leaflets of transcatheter valve prostheses contain a greater quantity of metal in the stent frame in contrast to the surgical valves. This factor may change the outcome and management of IE\[[@pone.0225077.ref023]\].

There is limited data on infective endocarditis after TAVI, its microbiological profile, clinical outcomes and treatment modalities. Most of the data is limited to case reports and small series, which can lead to publication bias\[[@pone.0225077.ref019]\]. In the prospective randomized Placement of Aortic Transcatheter Valves (PARTNER) trial, the incidence of infective endocarditis after TAVI is reported from 0.1% to 3.03%, with no difference between TAVI and SAVR\[[@pone.0225077.ref024],[@pone.0225077.ref025]\]. According to other studies, infective endocarditis occurs in 0.5% to 3.1% of patients after TAVI\[[@pone.0225077.ref026],[@pone.0225077.ref027]\]. Similar incidence rates of infective endocarditis are reported after surgical valve replacement\[[@pone.0225077.ref028]\].

[Fig 1](#pone.0225077.g001){ref-type="fig"} shows the transesophageal (long and short-axis) view and fluoro-deoxyglucose positron emission tomography of the post-TAVI endocarditis and [Fig 2](#pone.0225077.g002){ref-type="fig"} illustrates theprocedure of TAVI.

!["Transcatheter heart valve (THV) endocarditis.\
A. Long-axis transesophageal view showing typical vegetation attached to the ventricular side of a THV (red arrow). B. Short-axis transesophageal view showing de novo peri-prosthetic echo-free cavities and thickened areas (red arrow). C. 4 fluoro-deoxyglucose positron emission tomography (FDG-PET) depicting cells with an enhanced glucose metabolism at the level of THV, thus corroborating the diagnosis of endocarditis" \[[@pone.0225077.ref029]\].](pone.0225077.g001){#pone.0225077.g001}

!["The JenaValve transcatheter heart valve (THV) prosthesis (JenaValve Technology GmbH, Munich, Germany), a trileaflet porcine root tissue valve attached to a nitinol stent (A) and its implantation in illustration (B to D) and fluoroscopy (E to H). Release of the positioning feelers and placement into the aortic sinuses enables anatomic orientation (B and F). After correct orientation has been verified in 2 different fluoroscopic angulations, release of the lower stent part facilitates the clipping of the native aortic valve leaflets to the device and expansion of the stent allowing for secure anchoring even in the absence of valve calcium (C and G). Release of the upper stent part completes deployment of the valve prosthesis (D and H)" \[[@pone.0225077.ref018]\].](pone.0225077.g002){#pone.0225077.g002}

The clinical picture of post-TAVI IE varies from nonspecific symptoms to acute infection or sepsis with fever, heart failure or embolic stroke. As most of these patients are elderly, they frequently present with atypical symptoms and signs. Greater than 50% of the patients present with heart failure and 20% have non-specific symptoms e.g. malaise, weakness or weight loss. High-grade fever and heart murmur are relatively less common in post-TAVI IE as compared to native valve IE. The diagnosis of post-TAVI IE by echocardiography is more difficult than native valve IE due to differences in the technique of valve implantation. The detection of small vegetation in post-TAVI IE is limited as the valve contains large amounts of metal which create reflectance and a shadowing effect \[[@pone.0225077.ref030]\]. According to guidelines, early surgery is indicated in complicated cases of post-TAVI IE. Because these patients are high-risk, surgery is contraindicated in most of the patients with post-TAVI IE \[[@pone.0225077.ref031]\].

Rationale {#sec007}
---------

Infective endocarditis is a rare but fatal complication of TAVI with its incidence ranging from 0.1%-3.03%. It has a high mortality rate with many complications \[[@pone.0225077.ref001],[@pone.0225077.ref023]\].Transcatheter aortic valve implantation is gaining popularity day by day because it is feasible, less invasive technique and the only treatment option in patients at high surgical risk for severe symptomatic aortic stenosis \[[@pone.0225077.ref011]\]. Due to this, the incidence of post-TAVI infective endocarditis is expected to rise in the coming years. The data on infective endocarditis after TAVI is scarce and limited to case reports and case series in the literature \[[@pone.0225077.ref019],[@pone.0225077.ref020]\]. It is the need of the hour to analyze the available data on post-TAVI infective endocarditis from the available literature. This study wasdesigned to conduct a systematic review of the incidence of infective endocarditis after TAVI, the causative pathogens isolated from these patients and the clinical outcomes. It will help us to improve the antibiotic prophylaxis strategies and treatment options for infective endocarditis in the context of TAVI.

Objectives {#sec008}
==========

The objectives of this systematic review were to evaluate the incidence of infective endocarditis after TAVI, its microbiological profile and clinical outcomes.

Material and methods {#sec009}
====================

The study was done according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and is registered with PROSPERO International Prospective Register of Systematic Reviews (PROSPERO registration number CRD42018115943).

Eligibility criteria {#sec010}
--------------------

The following criteria were used for the selection of studies:

Study designs {#sec011}
-------------

The retrospective, prospective and observational studies were eligible for the systematic review. The case reports and case series were excluded.

Participants {#sec012}
------------

The studies included adult humans of either gender with age ≥70 years who underwent TAVI. The minimum follow-up time was 6 months.

Interventions {#sec013}
-------------

The intervention was TAVI. Healthcare provision and follow-up of the patients after TAVI to look for the incidence of infective endocarditis & its clinical outcomes. Investigating the causative organisms of infective endocarditis.

"Transcatheter heart valve endocarditis is defined following Duke's modified criteria or evidence of abscess/paravalvular leak/pus/vegetation confirmed as secondary to infection by histological or bacteriological studies or evidence of abnormal tracer uptake around the site of the prosthetic valve by F-fluoro-deoxyglucose positron emission tomography\"\[[@pone.0225077.ref029]\].

Comparators {#sec014}
-----------

There was no control group for comparison.

Outcomes {#sec015}
--------

The primary outcome was:

1.  Incidence of post-TAVI infective endocarditis

The secondary outcomes were:

1.  Microbiological profile of infective endocarditis

2.  MACE including in-hospital mortality & mortality at follow-up, heart failure, stroke, major bleeding and arrhythmias

3.  NACE including septic shock

4.  Surgical intervention

5.  Valve-in-valve procedure

"Sepsis is defined as an infection that triggers a particular Systemic Inflammatory Response Syndrome (SIRS). This is characterized by body temperature outside 36°C---38°C, HR \>90 beats/min, respiratory rate \>20/min, WBC count \>12,000/mm3 or \<4,000/mm3. Patients with infections plus two or more elements of the SIRS meet the criteria for sepsis. Those who have end organ failure are considered as having severe sepsis; and those who have refractory hypotension along with the above said criteria are considered to be in septic shock \[[@pone.0225077.ref032]\]."

Timing {#sec016}
------

All the included studies had a follow-up time of at least 6 months after TAVI.

Setting {#sec017}
-------

The study conducted in any type of setting was included.

Language {#sec018}
--------

Studies reported in the English language only.

Information sources {#sec019}
-------------------

All the relevant articles in English with text words related to infective endocarditis and transcatheter aortic valve implantation (TAVI) were searched in MEDLINE (PubMed), EMBASE (OVID interface) and the Cochrane Central Register of Controlled Trials (Wiley interface) till October 2018. The literature search was limited to human subjects. The case reports and case series were excluded.

Search strategy {#sec020}
---------------

Medline, EMBASE and the CENTRAL trials registry of the Cochrane Collaboration were searched for keywords, including 'Transcatheter aortic valve implantation', 'Transcatheter aortic valve replacement', 'TAVI', 'TAVR', 'Endocarditis', 'Infective endocarditis', 'Prosthetic valve endocarditis', 'Infective endocarditis after TAVI', 'Incidence and clinical impact of infective endocarditis on TAVI', 'TAVI-associated infective endocarditis', 'Prosthetic valve endocarditis after transcatheter valve replacement', 'Causative organisms of post-TAVI infective endocarditis', 'Clinical outcomes of infective endocarditis after TAVI', 'In-hospital mortality', 'Mortality at follow-up', 'Transcatheter heart failure' and 'Outcomes of TAVI'.

Data management, selection process and data collection {#sec021}
======================================================

The first and second authorswere the principal investigators. Each author individually read all the relevant articles. The articles meeting the eligibility criteria were included for the systematic review. The search results from each database were saved in EndNote X9 and duplicates were removed.

Data items {#sec022}
----------

Data was recorded and tabulated including author name, year of publication, sample size, study type, follow-up time, mean age & gender of patients, primary and secondary outcomes. It ensured uniformity between the authors and integration of findings.

Outcomes and prioritizations {#sec023}
----------------------------

The outcomes were the incidence of infective endocarditis after TAVI, its microbiological profile and clinical outcomes of infective endocarditis.

Data synthesis {#sec024}
--------------

The search strategy shortlisted 137 articles, out of which 44 articles were relevant. Forty four articles on infective endocarditis in post-TAVI patients were assessed for full text. Out of these, 11 studies were included in the systematic review. All the studies were retrospective or observational with the follow-up duration of at least 6 months. Thirty three articles did not meet the inclusion criteria as these were case reports, case series and systematic reviews. The meta-analysis could not be done as there was no control group for comparison.The PRISMA flow diagram for the study protocol is shown in [Fig 3](#pone.0225077.g003){ref-type="fig"}.

![PRISMA flow diagram.](pone.0225077.g003){#pone.0225077.g003}

Data analysis {#sec025}
-------------

The data entry and analysis was done using the Statistical Package for the Social Sciences (SPSS) version 25. The follow-up duration and incidence of IE were evaluated as mean. The microbiological profile and clinical outcomes of post-TAVI IE were expressed as frequency and percentage.

### Risk of bias {#sec026}

The Newcastle-Ottawa-Scale was used to calculate the risk of bias in the included studies as shown in [Table 2](#pone.0225077.t002){ref-type="table"}.

10.1371/journal.pone.0225077.t002

###### Risk of bias in individual studies.

![](pone.0225077.t002){#pone.0225077.t002g}

  Study/Author                                    Selection   Comparability   Exposure                                                          
  ----------------------------------------------- ----------- --------------- -------------- -------------- -------------- ----- -------------- -----
  **Amat-Santos\[[@pone.0225077.ref023]\]**       Low         Low             Low            Low            Low            Low   Low            Low
  **Puls\[[@pone.0225077.ref034]\]**              Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low
  **Latib\[[@pone.0225077.ref033]\]**             Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low
  **Olsen\[[@pone.0225077.ref027]\]**             Low         Low             Low            Low            Low            Low   Low            Low
  **Martinez-Selles\[[@pone.0225077.ref022]\]**   Low         Low             Low            Low            Low            Low   Low            Low
  **Regueiro\[[@pone.0225077.ref028]\]**          Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low
  **Seiffert\[[@pone.0225077.ref018]\]**          Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low
  **Spartera\[[@pone.0225077.ref029]\]**          Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low
  **Kosek\[[@pone.0225077.ref036]\]**             Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low
  **Gallouche\[[@pone.0225077.ref035]\]**         Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low
  **Doss\[[@pone.0225077.ref037]\]**              Low         Low             Some concern   Some concern   Some concern   Low   Some concern   Low

Results {#sec027}
=======

A total of 44 articles on infective endocarditis in TAVI patients were assessed for full-text. Thirty three articles were excluded as these articles were case reports, case series and systematic reviews. Eleven articles were included in this systematic review with the average duration of follow-up 474 days (1.3 years). [Table 3](#pone.0225077.t003){ref-type="table"} shows the important parameters of the included studies.

10.1371/journal.pone.0225077.t003

###### Characteristics of included studies.

![](pone.0225077.t003){#pone.0225077.t003g}

  Study/Author                                    Year   Study Type      Journal                  Sample size   Follow-up       Mean Age (years)All TAVI patients   Mean Age (years)THV-e patients   Gender All TAVI patients             GenderTHV-e patients
  ----------------------------------------------- ------ --------------- ------------------------ ------------- --------------- ----------------------------------- -------------------------------- ------------------------------------ -----------------------------------
  **Amat-Santos\[[@pone.0225077.ref023]\]**       2015   Retrospective   Circulation              7944          1.1±1.2 years   81±8                                79±8                                                                  23(43.4%) females30(56.6%) males
  **Puls\[[@pone.0225077.ref034]\]**              2013   Prospective     Eurointervention         180           319 days                                            83.4                                                                  3(60%) females2(40%) males
  **Latib\[[@pone.0225077.ref033]\]**             2014   Retrospective   J Am Coll Cardiol        2572          393 days                                            80±6                                                                  
  **Olsen\[[@pone.0225077.ref027]\]**             2015   Retrospective   Circ Cardiovasc Interv   509           1.4 years       80±6.9                              78±6.9                           213(42%) females296(58%) males       1(6%) female17(94%)males
  **Martinez-Selles\[[@pone.0225077.ref022]\]**   2016   Prospective     Eurointervention         952           423 days        79.5                                                                                                      4(40%) females6(60%) males
  **Regueiro\[[@pone.0225077.ref028]\]**          2016   Retrospective   JAMA                     20006         10.5 months     81.8                                78.9                                                                  91(36.4%) females159(63.6%) males
  **Seiffert\[[@pone.0225077.ref018]\]**          2014   Retrospective   J Am Coll CardiolIntv    31            235 days        73.8±9.1                                                             11(35.5%) females20(64.5%) males     
  **Spartera\[[@pone.0225077.ref029]\]**          2018   Retrospective   Echocardiography         621           402 days        80±7.9                              78±6.5                           333(53.6%) females288(46.4%) males   4(50%) females4(50%) males
  **Kosek\[[@pone.0225077.ref036]\]**             2015   Retrospective   Kardiol Pol              7             12 months       77.7                                80                               4(57%) females3(43%) males           1 male
  **Gallouche\[[@pone.0225077.ref035]\]**         2018   Retrospective   J Hosp Infect            326           460 days        85                                  79.8                             191(58.6%) females135(41.4% males    5(83.3%) females1(16.7%) male
  **Doss\[[@pone.0225077.ref037]\]**              2012   Prospective     Ann Thorac Surg          100           3.8±2 years     85±6 years                                                           71(71%) females29(29%) males         

**TAVI:** Transcatheter aortic valve implantation, **THV-e:** Transcatheter heart valve endocarditis

Out of 11 included articles,the incidence of infective endocarditis varied from 0%-14.3%, the mean is 3.25%. This may be attributed to hospital, cardiologist and patient-related factors or the sample size. The incidence of post-TAVI infective endocarditis is shown in [Fig 4](#pone.0225077.g004){ref-type="fig"}.

![Percentage of post-TAVI infective endocarditis in studies included in the systematic review.\
The microbiological profile of post-TAVI infective endocarditis is reported in 8 studies. *Enterococci* are the most common causative organism isolated from 25.9% of cases followed by *Staphylococcus aureus* (16.1%), *coagulase-negative Staphylococcus* species (14.7%), other *Streptococcus* species (12.5%), *Viridans streptococci* (8.5%), gram negative rods/*HACEK*/*candida* species (11%) and polymicrobial (0.42%).The cultures were negative in 6.7% of cases. The causative organisms of infective endocarditis are shown in [Fig 5](#pone.0225077.g005){ref-type="fig"}.](pone.0225077.g004){#pone.0225077.g004}

![Causative organisms of post-TAVI infective endocarditis.\
The in-hospital mortality and mortality at follow-up were assessed in 7 studies with the mean incidence of 29.5% in-hospital mortality and 29.9% mortality at follow-up. The incidence of heart failure after post-TAVI infective endocarditis was reported in 5 studies making a cumulative incidence of 37.1%. Two studies determined the incidence of stroke with the stroke occurring in 10.5% and 0% post-TAVI infective endocarditis patients. Major bleeding was reported in 2 studies with an average of 11.3%. Only a single study by Martinez-Selles et al. reported arrhythmias in 20% cases. The septic shock occurred in 10% and 27.7% post-TAVI infective endocarditis patients according to 2 studies. The surgical intervention for the treatment of post-TAVI infective endocarditis was reported in 7 studies with the mean of 11.4%. Four studies revealed the valve-in-valve procedure performed in an average of 6.4% cases. The clinical outcomes of post-TAVI infective endocarditis are shown in [Fig 6](#pone.0225077.g006){ref-type="fig"}.](pone.0225077.g005){#pone.0225077.g005}

![Clinical outcomes in patients of post-TAVI infective endocarditis.\
The incidence of infective endocarditis in the included studies with its causative organisms are summarized in [Table 4](#pone.0225077.t004){ref-type="table"}.](pone.0225077.g006){#pone.0225077.g006}

10.1371/journal.pone.0225077.t004

###### Incidence of post-TAVI infective endocarditis in the included studies with its causative organisms.

![](pone.0225077.t004){#pone.0225077.t004g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Amat-Santos                               Puls                          Latib                                Olsen                         Martinez-Selles                 Regueiro                                                                Seiffert   Spartera                        Kosek      Gallouche                        Doss
  ----------------------------------------- ----------------------------- ------------------------------------ ----------------------------- ------------------------------- ----------------------------------------------------------------------- ---------- ------------------------------- ---------- -------------------------------- ------
  **Incidence of Infective Endocarditic**                                                                                                                                                                                                                                                                                                   

  53(0.67%)                                 5(2.8%)                       29(1.13%)                            18(3.5%)                      10(1.1%)                        250(1.3%)                                                               1(3.2%)    8(6%)                           1(14.3%)   6(1.8%)                          0

  **Causative Organisms**                                                                                                                                                                                                                                                                                                                   

  *CoNS* 13(24.5%)                          *Enterococci*2(40%)           *Enterococci*5(17.24%)               *Enterococci* 6(33%)          *Enterococci* 3(30%)            *Enterococci* 57(24.6%)                                                            *Enterococci* 2(25%)                       *Staph aureus* 1(16.67%)         

  *Staph aureus* 11(20.75%)                 *Staph aureus* 1(20%)         *CoNS* 4(13.8%)                      *Staph aureus* 4(22%)         *Other Streptococc*2(20%)       *Staph aureus* 54(23.3%)                                                           *Viridans* 2(25%)                          *CoNS* 1(16.67%)                 

  *Enterococci* 11(20.75%)                  Other *Streptococci* 1(20%)   *Staph aureus* 4(13.8%)              *Viridans*3(17%)              *Viridans* 1(10%)               *CoNS*41(16.8%)                                                                    *CoNS*2(25%)                               *Enterococci*1(16.67%)           

  *Viridans* 3(5.7%)                        GNR 1(20%)                    *Viridans* 1(3.45%)                  *Other Streptococci* 3(17%)   *CoNS* 1(10%)                   *Viridans* 16(6.9%)                                                                *Staph aureus* 1(12.5%)                    Other *Streptococci* 1(16.67%)   

  Others 13(24.5%)                                                        *Other Streptococci* 4(13.8%)        *CoNS*2(11%)                  GNR 2(20%)                      Negative Cultures 12(5.2%)                                                         Other *Streptococci* 1(12.5%)              GNR 1(16.67%)                    

  Negative cultures 2(3.8%)                                               *HACEK* 1(3.45%)                                                   *Candida parapsilosis* 1(10%)   \[Information for causative organisms is available for 180 patients\]                                                         Negative culture 1(16.67%)       

                                                                          GNR 1(3.45%)Polymicrobial 1(3.45%)                                                                                                                                                                                                                                

                                                                          Negative cultures 5(17.24%)\                                                                                                                                                                                                                                      
                                                                          Not available 3(10.34%)                                                                                                                                                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

***CoNS***: *Coagulase-negative Staphylococcus* species, ***Staph aureus*:** *Staphylococcus aureus*, **GNR:** Gram negative rod, ***HACEK*:***Haemophilus*species, *Actinobacillus*, *Cardiobacterium hominis*, *Eikenellacorrodens* and *Kingella* species

**Polymicrobial:** Blood cultures of 1 patient was positive for *Enterococcus faecalis* and *coagulase-negative Staphylococci*

The clinical outcomes of post-TAVI infective endocarditis are summarized in [Table 5](#pone.0225077.t005){ref-type="table"}.

10.1371/journal.pone.0225077.t005

###### Clinical outcomes of post-TAVI infective endocarditis.

![](pone.0225077.t005){#pone.0225077.t005g}

  Amat-Santos                    Puls       Latib           Olsen      Martinez-Selles   Regueiro        Seiffert   Spartera   Kosek      Gallouche      Doss
  ------------------------------ ---------- --------------- ---------- ----------------- --------------- ---------- ---------- ---------- -------------- ------
  **MACE**                                                                                                                                               
  In-hospital Mortality                                                                                                                                  
  25(47.2%)                                 *13(44*.*8%)*   *2(11%)*   *2(20%)*          *90(36%)*                             1(14.3%)   *2(33*.*3%)*   
  Mortality at Follow-up                                                                                                                                 
  13(24.5%)                      *2(20%)*   *5(17*.*2%)*    *2(11%)*   *3(30%)*          *50(31*.*5%)*              *6(75%)*                             
  Heart Failure                                                                                                                                          
  36(67.9%)                      1(20%)     9(31%)                     3(30%)            87(36.6%)                                                       
  Stroke                                                                                                                                                 
                                                                                         25(10.5%)       0                                               
  Major Bleeding                                                                                                                                         
                                                            2(11%)                       29(11.6%)                                                       
  Arrhythmias                                                                                                                                            
                                                                       2(20%)                                                                            
  **NACE**                                                                                                                                               
  Septic Shock                                                                                                                                           
                                                                       1(10%)            66(27.7%)                                                       
  **Surgical intervention**                                                                                                                              
  4(7.5%)                        1(20%)     3(10.3%)        1(5.6%)    2(20%)            37(14.8%)       1(3.2%)                                         
  **Valve-in-Valve Procedure**                                                                                                                           
  2(3.8%)                                   1(3.4%)         3(17%)                       3(1.2)                                                          

Out of 11 included studies, the data on antibiotic prophylaxis is detailed in 2 studies by Regueiro et al. and Amat-Santos et al. In a study by Regueiro et al., β lactam antibiotics were given in 195(78%) patients and vancomycin in 15(6%) patients for prophylaxis \[[@pone.0225077.ref028]\]. Amat-Santos et al. reported in his study that all patients with post-TAVI IE received prophylactic antibiotics (n = 53). Cephalosporins, vancomycin and penicillin were given in 30(56.6%), 14(26.4%) and 9(17%) patients, respectively \[[@pone.0225077.ref023]\].

Latib et al. conducted a multicenter study in which he stated that all the patients were given prophylactic antibiotics depending on institutional practices. However, the details of these antibiotics are not mentioned in the article \[[@pone.0225077.ref032]\]. In a study by Olsen et al., patients received prophylactic antibiotics (amoxicillin or roxithromycin) only before undergoing invasive dental procedure \[[@pone.0225077.ref027]\].

Studies by Regueiroet al., Amat-Santos et al., Martinez-Selles et al., Puls et al. and Olsen et al. mentioned the antibiotics used for the treatment of post-TAVI IE. Regueiro et al. reported in his study that 164 post-TAVI IE patients were treated with β lactam antibiotics (only β lactam antibiotics in 38 patients and in combination with other antibiotics in 126 patients) and vancomycin was used in 53 patients \[[@pone.0225077.ref028]\].

In a study by Amat-Santos et al., all the patients with post-TAVI IE were treated with prolonged antibiotic therapy of 4 weeks. β lactam antibiotics, gentamicin and vancomycin were given in 21(39.6%), 20(37.7%) and 16(30.2%) patients. Seven patients with positive blood cultures for *Staphylococcusaureus* and *Staphylococcusepidermidis* received rifampicin. Five of the 6 patients with post-TAVI IE due to methicillin-resistant *Staphylococcusaureus* received daptomycin \[[@pone.0225077.ref023]\]. Some patients had received antibiotics in combination. That is why the percentage of antibiotics is not 100%.

The antibiotics used for treating post-TAVI IE in 18 patients in a study by Oslen et al. were vancomycin in combination with linezolid/rifampicin in 5 patients, penicillin or ampicillin or dicloxacillin in combination with gentamicin/fusidic acid/linezolid/rifampicin in 8 patients, cefuroxime or ceftriaxone in combination with fusidic acid/ciprofloxacin/rifampicin in 5 patients \[[@pone.0225077.ref027]\].

Puls et al. mentioned the following antibiotics used for treating 5 patients with post-TAVI IE: vancomycin & rifampicin alone or in combination with gentamicin in 2 patients, ampicillin with ciprofloxacin/gentamicin in 1 patient and ceftriaxone in 1 patient. One patient received parenteral antibiotics, the names of which are not mentioned in the study \[[@pone.0225077.ref034]\].

In a study by Martinez-Selles et al., out of 10 post-TAVI IE patients, 9 patients received β lactam antibiotics. Two out of these 9 patients were also given aminoglycosides. One patient had fungal endocarditis and was treated with fluconozole&caspofungin \[[@pone.0225077.ref022]\]. The antibiotics used for the treatment of post-TAVI IE in 5 studies are tabulated in [Table 6](#pone.0225077.t006){ref-type="table"}.

10.1371/journal.pone.0225077.t006

###### Antibiotics used for treatment of post-TAVI IE in 5 studies.

![](pone.0225077.t006){#pone.0225077.t006g}

  Study                                                    Antibiotics                                      
  -------------------------------------------------------- ------------- ----------- ----------- ---------- ---------
  **Regueiro[\*](#t006fn001){ref-type="table-fn"}**        164(75.6%)    53(24.4%)                          
  **Amat-Santos[\*\*](#t006fn002){ref-type="table-fn"}**   21(39.6%)     16(30.2%)   20(37.7%)   7(13.2%)   5(9.4%)
  **Martinez-Selles**                                      9(90%)                                           
  **Olsen**                                                13(72.2%)     5(27.8%)                           
  **Puls**                                                 2(40%)        2(40%)                             

\*217 patients were treated with antibiotics.

\*\* Some patients had received antibiotics in combination. That is why the percentage of antibiotics is not 100%.

Discussion {#sec028}
==========

The results of our study showed that the mean incidence of post-TAVI IE is 3.25%. The most common causative organism is *Enterococci* (25.9%) followed by *Staphylococcus aureus* (16.1%) and *coagulase-negative Staphylococcus* species (14.7%). Amat-Santos et al. also reported *Enterococci* (34.4%) as the most common organism causing IE after TAVI but the second common organism was *coagulase-negative Staphylococcus* species (18.7%) \[[@pone.0225077.ref026]\]. In contrast, in a systematic review by Eisen et al., *coagulase-negative Staphylococcus* species was the most common (30%) cause of post-TAVI IE followed by *Enterococci* (20%) \[[@pone.0225077.ref019]\].

In our study, the mean incidence of in-hospital mortality is 29.5% and mortality at follow-up is 29.9%. Similarly, the high mortality rate was reported in other systematic reviews. Post-TAVI IE was responsible for 34.4% and 40% mortality in studies by Amat-Santos et al. and Eisen et al.,respectively \[[@pone.0225077.ref026],[@pone.0225077.ref019]\]. According to our study, surgical intervention and valve-in-valve procedure for the treatment of post-TAVI infective endocarditis were performed in 11.4% and 6.4% of the cases, respectively. Amat-Santos et al. and Eisen et al.reported surgical intervention in 40% and 30% of the post-TAVI IE patients, respectively which is much higher than our results \[[@pone.0225077.ref026],[@pone.0225077.ref019]\].

A systematic review was done on infective endocarditis after transcatheter aortic and pulmonary valve replacement. Twenty eight articles published between 2000 and 2013 including 16 on TAVI were analyzed with 32 post-TAVI infective endocarditis patients. The follow-up duration was 3 to 9 months. According to this review, *Enterococci* were the most common organism of IE after TAVI accounting for 11(34.4%) of the cases. Other organisms isolated were *coagulase-negative Staphylococcus* species in 6(18.7%), other *Streptococcus* species in 5(15.6%), *Staphylococcus aureus* in 2(6.3%), gram negative rods in 2(6.3%), *Moraxella* in 1(3.1%), *Candida albicans* in 1(3.1%), *Histoplasma* in 1(3.1%) and *Corynebacterium* in 1(3.1%). Two (6.3%) patients had negative blood cultures. The patients presented with fever, chills, anorexia, congestive heart failure, stroke, hemiparesis, sepsis and limb ischemia. Thirteen (41%) patients required surgical intervention and 11(34.4%) patients died due to infective endocarditis\[[@pone.0225077.ref026]\].

Another systematic review was conducted by Eisen et al. including 10 cases, 8 were from case reports and 2 cases were presented in congresses. The microorganisms isolated from blood cultures were *coagulase-negative Staphylococcus* species in 3(30%), *Enterococci* in 2(20%), *Candida albicans*,*Moraxella*, *Corynebacterium*, other *Streptococcus* species and *Histoplasma* (1 in each) patients. Three (30%) patients underwent surgery and 4(40%) patients died after post-TAVI infective endocarditis\[[@pone.0225077.ref019]\]. The major limitation of these systematic reviews was that most of the included articles were case reports and case series which may have precluded the real evaluation of the post-TAVI infective endocarditis. Lastly, certain cases of post-TAVI infective endocarditis might not have been published leading to potential publication bias.

A retrospective multicenter study was conducted in 21 centers in America and Europe. A total of 7944 patients underwent TAVI out of which 53(0.67%) patients developed infective endocarditis. The mean follow-up time of patients was 1.1±1.2 years. Antibioticprophylaxis was given in all centers during the TAVI procedure. Cephalosporins, vancomycin and piperacillin/tazobactam were used in 14(67%), 6(28%) and 1(5%) centers respectively. In most of the centers, a single antibiotic dose was administered except 2 centers in which 2--3 doses were also given after TAVI. *Coagulase-negative Staphylococcus* specieswas the most causative organism isolated from 13(24.5%) cases.*Staphylococcusaureus*, *Enterococci and Viridans streptococci* were isolated from 11(20.8%), 11(20.8%) and 3(5.7%) patients, respectively. Infective endocarditis was caused by atypical microorganisms such as *Escherichia coli*, *Serratia*, *Acinetobacter*, *Candida lusitaniae*in 13(24.5%) patients. In 2(3.8%) patients, cultures were negative. The most common complication of IE was heart failure in 36(67.9%) patients. The other complications were acute kidney injury, septic shock, systemic embolism, stroke and persistent infection. The patients were managed with surgical explantation (7.5%) and valve-in-valve procedure (3.8%). In-hospital mortality was reported in 25(47.2%) and mortality at follow-up in 13(24.5%) patients\[[@pone.0225077.ref023]\].

Another study reported the incidence and clinical outcomes of infective endocarditis after TAVI retrospectively from 2008 to 2013. The mean follow-up time was 393 days. Prophylactic antibiotics were given in all patients. Out of 2572 TAVI patients, 29(1.13%) patients developed infective endocarditis. The most frequent pathogen was *Enterococci*present in 5(17.2%) patients followed by *coagulase-negative Staphylococcus* species in 4(13.8%) patients. Other organisms isolated were *Staphylococcus aureus* in 4(13.8%), *Streptococci* other than *Viridans* in 4(13.8%), *Viridans streptococci* in 1(3.4%), *HACEK* in 1(3.4%), gram negative rods in 1(3.4%) and polymicrobial in 1 patient. Cultures were negative in 5(17.2%) and not available in 3(10.3%) patient. Heart failure occurred in one-third of the population. The outcomes of IE were in-hospital mortality in 13(44.8%) and mortality at follow-up in 5(17.2%) patients, surgery in 3(10.3%) and TAVR-in-TAVR in 1(3.4%) patient. The patients during follow-up died from the stroke (3), relapse of IE (1) and sepsis (1)\[[@pone.0225077.ref033]\].

A retrospective study was done on post-TAVI infective endocarditis from 2005 to 2015 including 47 centers in America and Europe. The follow-up time was 10.5 months. Among the 20006 patients who underwent TAVI, infective endocarditis occurred in 250(1.3%) patients. The data of causative pathogens was available for 180 patients. The most common organism was *Enterococci* found in 57(24.6%) cases followed by *Staphylococcus aureus* in 54(23.3%) patients. *Coagulase-negative Staphylococcus*speciesand *Viridans streptococci* were present in 41(16.8%) and 16(6.9%) patients, respectively. Negative cultures were reported in 12(5.2%) cases. The complications of infective endocarditis were heart failure (36.6%), in-hospital mortality (36%), surgical intervention (14.8%), transcatheter valve-in-valve procedure (1.2%), pacemaker extraction (2.8%), recurrent IE (9.4%) and death during follow-up (31.5%)\[[@pone.0225077.ref028]\].

Another study reported 739 cases of IE from 26 Spanish hospitals. Ten (1.1%) cases of post-TAVI infective endocarditis occurred out of total 952 TAVI patients and 221(29.9%) after SAVR. The organisms isolated were as follows: *Enterococci* in 3(30%), *Viridans streptococci* in 1(10%), other *Streptococci* in 2(20%), *coagulase-negative Staphylococcus* species in 1(10%), *Salmonella enteritidis* in 1(10%), *Acinetobacter* in 1(10%) and *Candida parapsilosis* in 1(10%) patient. Three (30%) patients developed heart failure, 1(10%) underwent surgery, 1(10%) had a relapse of IE, 2(20%) patients died during hospitalization and 3(30%) during follow-up\[[@pone.0225077.ref022]\].

In Denmark, a study was done including 509 consecutive post-TAVI patients. Eighteen (3.5%) patients developed infective endocarditis during the follow-up of 1.4 years. Blood culture revealed *Enterococci* in 6(33%), *Staphylococcus aureus* in 4(22%), *Viridans streptococci* in 3(17%), other *Streptococci* in 3(17%) and *coagulase-negativeStaphylococcus*speciesin 2 cases (11%). The outcomes of IE were in-hospital mortality in 2(11%), mortality at follow-up in 2(11%), surgical intervention in 1(5.6%), a transcatheter valve-in-valve procedure in 3(17%) and pacemaker implantation in 4(22%)\[[@pone.0225077.ref027]\].

In another study, 180 consecutive post-TAVI patients were followed up to 319 days. Five (2.8%) cases of infective endocarditis occurred during that period. The following pathogens were isolated from the blood cultures of the patients: *Enterococci* in 2(40%), *Staphylococcus aureus* in 1(20%), other *Streptococcus* species in 1(20%) and gram negative rods in 1(20%) patient. One patient developed heart failure (20%), 1(20%) patient underwent surgery and 2(40%) patients died after infective endocarditis\[[@pone.0225077.ref034]\].

In Grenoble Alpes University Hospital France, a retrospective study was done on 326 patients who underwent TAVI with the average follow-up period of 460 days. Out of 326 patients, 6(1.8%) patients were diagnosed with infective endocarditis. Blood cultures were positive in 5 and negative in 1 patient. The pathogens responsible in 5 patients were *Staphylococcus aureus*, *coagulase-negative Staphylococcus* species, *Enterococci*, *Streptococcus* speciesand *Escherichia coli*. Two patients died after infective endocarditis, one 17 days and another 40 days after IE\[[@pone.0225077.ref035]\].

Kosek et al. retrospectively analyzed 7 patients with bicuspid aortic valve who underwent TAVI at the Institute of Cardiology, Poland. A total of 104 patients had TAVI at the institution and 7 of them had the bicuspid aortic valve. These patients were followed up to 12 months after TAVI. One patient developed infective endocarditis and died after 30 days of the procedure\[[@pone.0225077.ref036]\].

A study was carried out on 100 patients who underwent TAVI in Germany. The average follow-up duration was 3.8±2 years. The outcomes assessed were 30-day mortality, 5-year mortality, infective endocarditis, embolization, reintervention, stroke and valve thrombosis. None of the patients developed endocarditis\[[@pone.0225077.ref037]\].

Another study analyzed the outcomes of TAVI in patients with severe aortic regurgitation. Thirty one patients were included from 9 German centers. The follow-up time was 235 days. During follow-up, one of the patients had infective endocarditis and required surgical intervention (SAVR)\[[@pone.0225077.ref018]\].

Another retrospective study was performed in Italy in which 621 post-TAVI patients were followed for 402 days. Eight (6%) patients developed infective endocarditis. The microorganisms isolated were *Enterococci* in 2, *Viridans streptococci* in 2, *coagulase-negativeStaphylococcus*species in 2, *Staphylococcus aureus* in 1 and *Streptococcus* speciesin 1 patient. The mortality rate was 75% in patients\[[@pone.0225077.ref029]\].

Conclusions {#sec029}
===========

The incidence of post-TAVI infective endocarditis is low being 3.25% but it is associated with high mortality and complications. The most common complication is heart failure with a cumulative incidence of 37.1%. *Enterococci*are the most common causative organism isolated from 25.9% of cases followed by *Staphylococcus aureus*in 16.1% of cases. Appropriate measures should be taken to prevent infective endocarditis in post-TAVI patients including adequate antibiotics prophylaxis directed specifically against these organisms.

Limitations of the study {#sec030}
========================

-   The meta-analysis could not be done as there was no control/comparison group in the included studies.

-   The outcomes of post-TAVI IE have not been integrated with the impact of different treatment options as none of the included studies correlated the outcomes with the treatment modality.

-   The review does not improve the discussion on IE prophylaxis, although the rationale sets this topic as a central objective. This is because the data on IE prophylaxis is not detailed in all the included studies.

Recommendations of the study {#sec031}
============================

-   Meticulous aseptic measures should be reinforced with special focus on sterilization and disinfection in the catheterization laboratory. The provision of laminar air flow has an added advantage.

-   Antibiotic prophylaxis should be given in TAVI patients. As *Enterococci* are the most common organism causing post-TAVI infective endocarditis, the prophylactic antibiotics should be given directed against this organism. The traditional use of cephalosporins should be reconsidered as *Enterococci* are intrinsically resistant to all cephalosporins.

Supporting information {#sec032}
======================
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Reviewer \#1: This article showed a metanalysis based on Infective Endocarditis Post-Transcatheter Aortic Valve Implantation (TAVI). Eleven articles were included in the systematic review. The authors wanted to study the incidence of infective endocarditis in post-TAVI as well as its microbiological profile and clinical outcomes.
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• (Page 12, table 5) It could be better if the authors split the table 5 into 2 different tables (one with the incidence and the ethology, and one with the outcomes.
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Reviewer \#2: This systematic review evaluated the incidence of infective endocarditis after transcatheter aortic valve implantation (TAVI).The incidence from 11 studies was 0 to 14.3% and the commonest organism was enterococcus.This was associated with a high mortality.

The study is of value as this is an emerging issue as transvalvular interventions evolve.

Rationale：sentences are made without references

Method: the analysis plan is not described

Results: standardized plots not reported，Results are mainly descriptive. Bias and validity was not assessed.

There are far too many figures. The value of the photography is unclear.

Discussion: It is recommended that the discussion be amended to begin with a statement of the principle findings as listed as the primary and secondary aims.Then a summary in 3-5 paragraphs as to how the findings of this systematic review are similar or different to other findings in the literature and possible reasons why this is so. Also discuss the limitations of the findings.

In general, abbreviations need to be pre- defined prior to use.

Reviewer \#3: Khan et al. present a systematic review on Infective Endocarditis (IE) occurring after Transcatheter Aortic Valve Implantation (TAVI). Analyzing 11 articles, they focused on the incidence, microbiological profiles and clinical outcome (i.e. mortality, stroke, bleedings, heart failure, septic shock, and arrhythmias) of IE. According to their conclusions post-TAVI IE is mostly linked to Enterococcus, while native valve IE is often associated to S. Aureus or Streptococcus; the mortality rate was about 30%; the

most common complication was heart failure.

Overall, the manuscript is not really well-written due to some grammar mistakes and lack of text fluidity, while the length is appropriate for a systematic review. Tables are globally well constructed and and figures appear explicative, but there is space for refinement in small layout imperfections.

I have the following points of criticism:

Major:

• The manuscript is not really well-written due to some English mistakes and no fluidity among different statements;

• Introduction explains TAVI and IE, but no identification of a central purpose and no explanation of what the study adds to the knowledge are clearly available;

• Discussion mentions Pulmonary Valve Replacement (PVR), despite not being even mentioned in the Introduction; moreover, no studies on PVR were included in the systematic review;

• Authors state that no other reviews or meta-analysis are available focusing on this topic, despite at least two well-written systematic reviews from Ando et al. and Amat-Santos et al. have been recently published; it might be interesting to show the limitations of these articles, trying to overcome them;

• It is mandatory to explain differences and similarities between native valve-IE and TAVI-IE; in particular, concentrating on different timing and diagnostic management;

• The review does not improve the discussion on IE prophylaxis, although the Rationale sets this topic as a central objective;

• It is necessary to explain why case report and more over case series were excluded from this systematic review;

• The Discussion sometimes merely mentions the results without making them homogeneous in light of literature evidences; there is a need for original arguments to make the Discussion more appealing.

• Authors do not include some relevant studies in the systematic review (i.e. Onsea et. al., Buellesfeld et al., Barbanti et al.).

• Since Authors have analysed only two articles focusing on stroke, mean of stroke incidence may be influenced by extreme values (0% vs. 10.3%);

• IE outcomes are analyzed and summarized, but it would be necessary to integrate them with the impact of different treatment options (i.e. antibiotics therapy, surgery) to be more specific;

Minor:

• Scientific English and grammar should be globally improved;

• All measures should be accompanied by a dispersion index;

• Figure 3 reports a wrong green underscore;

• Figure 4 has some troubles in the layout;

• Figure 5 has some needless dots in a caption;

• Line 278 contains a redundant "0";

• Table 5 at "valve-in-valve procedure" line miss a "%"; in addition, some words appear in italic as a mistake

Reviewer \#4: Please also include timeline of the literature search in the method section of the abstract.

Who are two independent investigators?

Figure 3 (search flowchart), suggest to use PRISMA 2009 Flow Diagram platform

Current quality of all figures are not acceptable. They are very difficult to evaluate. Will need higher quality for all of them.

Search terms in Medline and Embase are different. Please attach syntax used in each database as supplementary.

Please make the data for this review publicly available, possibly through the Open Science Framework (osf.io). Items to include: list of excluded studies, etc. Making data publicly available will promote the reproducibility of the review and is best practices for systematic reviews.
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0225077.r002

Author response to Decision Letter 0

4 Sep 2019

The manuscript has been revised as suggested by the reviewers. Each point has been explained in this document. The marked and unmarked copies of the revised manuscript have been submitted.

Journal Requirements:

• The manuscript meets PLOS ONE\'s style requirements, including those for file naming.

• The Supporting Information files have been included at the end of manuscript.

• The dates during which the electronic search was performed have been mentioned.

• Table 2 has been omitted from the manuscript.

• The caption for figure 3 has been included.

Answers to the Questions

Reviewer\'s Responses to Questions

Comments to the Author

4\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Partly

Reviewer \#4: Yes

The manuscript is technically sound and the data support the conclusions. The study is a systematic review which included all the relevant articles on post-TAVI infective endocarditis till October 2018. The literature search was systematically conducted on 3 electronic databases. Medline (Pubmed), Embase and the Cochrane Central Register of Controlled Trials. The conclusion of the study correlates with the data and is drawn from the results of the data analyzed.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: N/A

Reviewer \#4: N/A

The data is analyzed using mean, frequency & percentages and presented as tables & bar graphs. The meta-analysis could not be done as there was no comparison/control group.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

Reviewer \#4: Yes

The data of the manuscript is provided in the main text and supporting information. The data of systematic search is shown in data synthesis & PRISMA flow diagram. The important parameters of included students are tabulated in the results. The search strategy, Pubmed syntax and PRISMA checklist are provided in supporting information.\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: Yes

Reviewer \#4: Yes

The manuscript is written in standard English which is clear and correct. Any grammatical mistake has been corrected in the revised manuscript.\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1:

Major issues

• (Page 9, line 276) The data synthesis has been improved. The studies considered and the criteria which did not respect for the inclusion in the meta-analysis are mentioned.

• The antibiotic therapy during post-transcatheter aortic valve implantation infective endocarditis is not specified because the data on antibiotic therapy was not available in the included studies.

• The meta-analysis could not be done as there was no control/comparison group in the included studies.

Minor issues

• Name of the bacteria:

The name of Viridians streptococci has been changed to Viridans streptococci

Staphylococcus species: Species is written in non-italic style

• (Page 3, line 82) The Reference number is 1.

• (Page 3, line 83) The line has been rephrased.

• (page 9, line 278) The redundant 0 after the full stop has been deleted.

• (Page 12, table 5) The sum of the percentages of the microorganisms are corrected to make 100% in the Amat-Santos, Latib, Gallouche studies.

• (Page 12, table 5) Table 5 has been split into 2 different tables (one with the incidence & the etiology and one with the outcomes).

• (Page 13, line 331-332) In the relevant article, congestive heart failure is the presenting feature of post-TAVI IE. That is why the sum of the percentages are not 100%. The details have been mentioned in the manuscript.

• (Page 13, line 335, and in other lines) Enterococcus has been changed to Enterococci.

• (Page 14, line 347) The spelling of Staphylococcus has been corrected.

• (Page 14, line 351-353) The sentence has been rephrased.

Reviewer \#2:

• Rationale: The references of sentences have been mentioned in the rationale.

• Method: The analysis plan has been described.

• Results: The results are expressed as tables and presented as Box plots. The risk of Bias is calculated and shown in table 3.

• The figures have been uploaded in the format (TIF and PACE) as suggested by the journal.

• Discussion: The discussion has been amended with the principle findings of the study.

• Limitations of the findings: The limitations have been added.

• Abbreviations have been pre-defined prior to use.

Reviewer \#3:

Major:

• The manuscript has been checked for English mistakes.

• Introduction: TAVI and IE have been explained first with further details of post-TAVI IE. The central purpose and explanation of what the study adds to the knowledge are clearly mentioned in the rationale of the study.

• This systematic review is conducted on post-TAVI IE. The reference of a systematic review by Amat-Santos et al. has been mentioned in the discussion. Amat-Santos et al. conducted a systematic review on infective endocarditis after transcatheter aortic as well as pulmonary valve replacement.

• It has been stated in the introduction of the manuscript that the data on post-TAVI IE is limited and most of the available studies are case reports & case series. The systematic review by Amat-Santos et al. has been explained in the discussion. Most of the included studies in this review were also case reports and case series. The study by Ando et al. is a meta-analysis that compared the incidence of infective endocarditis following TAVI versus surgical aortic valve replacement. The study is published in 2019 whereas the literature search for our systematic review was conducted till October 2018.

Amat-Santos IJ, Ribeiro HB, Urena M, Allende R, Houde C, Bedard E, et al. Prosthetic valve endocarditis after transcatheter valve replacement: a systematic review. JACC Cardiovasc Interv. 2015 Feb; 8(2):334--46. doi: 10.1016/j.jcin.2014.09.013.

Ando T, Ashraf S, Villablanca PA, Telila TA,Takagi H, Grines CL, et al. Meta-analysis comparing the incidence of infective endocarditis following after transcatheter aortic valve implantation versus surgical aortic valve replacement. Am J Cardiol. 2019 Mar 1; 123(5):827-32. doi: 10.1016/j.amjcard.2018.11.031.

• The differences and similarities between native valve-IE and TAVI-IE; in particular, concentrating on different timing and diagnostic management have been mentioned in the introduction.

• The review does not improve the discussion on IE prophylaxis, although the Rationale sets this topic as a central objective. This is because the data on IE prophylaxis is not detailed in the included studies.

• The case reports and case series were excluded from this systematic review. This is because most of the included studies in the two systematic reviews (available in the literature) on post-TAVI IE were case reports & case series. The major limitation of these reviews was that it may have precluded the real evaluation of the post-TAVI infective endocarditis and certain cases of post-TAVI infective endocarditis might not have been published leading to potential publication bias. The details of these two systematic reviews by Amat-Santos et al. \[26\] & Eisen et al. \[19\] and their limitations have been mentioned in the discussion.

• The results of the study have been explained in the discussion along with comparison with the results of two systematic reviews available. The results of our systematic review cannot be compared with the findings of the included studies. The details of the included studies have been mentioned in the discussion.

• The studies by Onsea et. al., Buellesfeld et al. and Barbanti et al. were not included in the systematic review because these studies do not meet the inclusion criteria. The details of these studies with their references are given below:

� In a study by Onsea et al., a total of 73 TAVI patients were analyzed for the development of complications. Eleven patients developed infections but none of them was diagnosed with infective endocarditis \[1\].

� In a study by Barbanti et al., the patients who underwent TAVI were categorized into two groups: those with Society of Thoracic Surgeons (STS) score ≤7% and patients with a score \>7%. The outcomes of TAVI were compared between these 2 groups. The results showed that the patients with STS ≤7% had lower rates of all-cause and cardiovascular mortality at 3 years after transcatheter aortic valve implantation.

� In another study by Barbanti et al., the outcomes of TAVI were compared in patients discharged within 72 hours and after 3 days of the procedure. The study showed that discharge within 72 hours after TAVI is feasible and does not seem to jeopardise the early safety of the procedure \[3\].

� Buellesfeld et al. evaluated the outcomes and predictors of success of procedure in patients who underwent TAVI at two institutions in German & Switzerland. The reported rates of in-hospital mortality, myocardial infarction and stroke were 11.9%, 1.8% and 3.6%, respectively.

1\. Onsea K, Agostoni P, Voskuil M, Samim M, Stella PR. Infective complications after transcatheter aortic valve implantation: results from a single centre. Neth Heart J. 2012; 20:360--4. doi: 10.1007/s12471-012-0303-9.

2\. Barbanti M, Schiltgen M, Verdoliva S, Bosmans J, Bleiziffer S, Gerckens U, et al. Three-year outcomes of transcatheter aortic valve implantation in patients with varying levels of surgical risk (from the CoreValve ADVANCE Study). Am J Cardiol. 2016; 117(5):820-7.

3\. Barbanti M, Capranzano P, Ohno Y, Attizzani GF, Gulino S, Imme S, et al. Early discharge after transfemoral transcatheter aortic valve implantation. Heart. 2015; 101:1435-6. doi: 10.1136/heartjnl-2015-308415.

4\. Buellesfeld L, Wenaweser P, Gerckens U, Mueller R, Sauren B, Latsios G, et al. Transcatheter aortic valve implantation: predictors of procedural success---the Siegburg--Bern experience. Eur Heart J. 2010; 31:984--91. doi:10.1093/eurheartj/ehp570.

• There were only two articles reporting on stroke after post-TAVI IE. The mean of stroke incidence may be influenced by extreme values (0% vs. 10.3%). The mean of stroke has been omitted from the manuscript.

• Infective endocarditis outcomes have not been integrated with the impact of different treatment options (i.e. antibiotics therapy, surgery). Because none of the included study correlated the outcomes with the treatment modality.

Minor:

• Scientific English and grammar have been improved.

• The green underscore has been omitted in figure 3.

• Corrected copy of figure 4 has been submitted.

• Corrected copy of figure 5 has been submitted.

• Redundant "0" in line 278 has been omitted.

• The sign of % has been added after valve-in-valve procedure" in Table 5. In addition, some words which appear in italic as a mistake are corrected.

Reviewer \#4:

• The timeline of the literature search has been mentioned in the method section of the abstract.

• The first and second authors were the principal investigators who performed the literature search. It has been mentioned under the heading of data management, selection and data collection.

• Figure 3 (PRISMA flow diagram) has been made by using PRISMA 2009 Flow Diagram platform.

• The figures have been uploaded in the format suggested by the journal.

• The syntax used in Pubmed is attached in the supplementary file.
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Infective Endocarditis Post-Transcatheter Aortic Valve Implantation (TAVI), Microbiological Profile and Clinical Outcomes: A Systematic Review

PLOS ONE

Dear Adnan Khan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Our expert reviewer(s) have recommended some major revisions to your manuscript. Therefore, I invite you to respond to the reviewer(s)\' comments as below and revise your manuscript.

==============================

We would appreciate receiving your revised manuscript by Nov 02 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Wisit Cheungpasitporn, MD, FACP

University of Mississippi Medical Center

Twitter: \@wisit661 Email: <wcheungpasitporn@gmail.com> 
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I appreciate the suggested modification of the text, but I still have some doubts.

In particular the antibiotic therapy and the clinical characteristics of the cohort are not specified. For example, the presence of septic shock at the beginning, the developing of Multi-organ failure and Acute kid-ney failure have a deep impact on the mortality and the morbidity. The correct therapy, the empiric strategies, the fast changing of the therapy based on a microbial isolation and the timing of the treatment could change the clinical response and the presence of cardiological-releted complications.

I do not think this last version of the paper should be published, but a further integration with data about patient's characteristics and therapeutic strategies from papers that report it, could give a more complete view and justify final conclusions on cardiological outcomes.

Reviewer \#2: Suggest limitations be incorporated in discussion and the comments raised by reviewers have been addressed

Reviewer \#3: Khan et al. have resubmitted a systematic review on Infective Endocarditis (IE) occurring after Transcatheter Aortic Valve Implantation (TAVI). Analyzing 11 articles, they focused on the incidence, microbiological profiles and clinical outcome (i.e. mortality, stroke, bleedings, heart failure, septic shock, and arrhythmias) of IE. According to their conclusions post-TAVI IE is mostly linked to Enterococcus, while native valve IE is often associated to S. Aureus or Streptococcus; the mortality rate was about 30%; the most common complication was heart failure.

Overall, after the Authors\' revision the manuscript appear quite well-written with better text fluidity. The length is appropariate for a systematic review. Tables are globally well made and figures are explicative.

I would propose only the improvement of the following points of criticism:

Major:

• A rigorous definition of septic shock would be necessary;

Minor:

• All abbreviations could be better explained and revisited due to several futile repetitions;

• Line 418 contains a sentence with several grammar errors.

Reviewer \#4: The investigators should obtain more information on patient's characteristics, infection data and treatment from each included study and take it into consideration for additional analyses.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0225077.r004

Author response to Decision Letter 1

2 Oct 2019

Reviewer 1:

The patients of post-TAVI IE were diagnosed according to the Modified Duke's criteria. The data on antibiotic prophylaxis is detailed in 2 studies by Regueiro et al. and Amat-Santos et al. and it has been mentioned in the Results. The antibiotic therapy for post-TAVI IE has also been included in the manuscript. Recommendations have been added based on the conclusion of the manuscript.

Reviewer 3:

• The definition of sepsis and septic shock are included in the manuscript in study outcomes (Methodology).

• All abbreviations are first preceded by complete word. After that, only abbreviations are written in the manuscript.

• The grammatical mistakes of the line no. 418 (now line no. 457) have been corrected.

Reviewer 4:

The antibiotics used for treating post-TAVI IE are given in 5 studies. These details have been added in the results. The patients undergoing surgical treatment (valve explantation and valve-in-valve procedure) have already been included in the results. Due to the heterogeneity of data in the included studies, further analysis of the variables cannot be done.
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Dear Dr. Adnan Khan,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Wisit Cheungpasitporn, MD, FACP

University of Mississippi Medical Center

Twitter: \@wisit661 Email: <wcheungpasitporn@gmail.com> 
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Additional Editor Comments:

I want to commend the authors on their superb efforts to revise the manuscript according to all reviewers' suggestions. The quality of the manuscript has improved substantially.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: (No Response)

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Even if I understand the difficulty of finding all the data that I recommended, I think this last version is more complete and I appreciate the modification of the text introduced.

Infective Endocarditis Post-Transcatheter Aortic Valve Implantation is not so known and knowledge of the possible infective complications that could intercourse, the microorganism implicated and the outcomes instead are important data in order to choose the better treatment that can be given to the patient.

Finally, with this last version this work is deeply improved and now I think it could be published.

Reviewer \#2: Overall all comments have been addressed as highlighted by each of the reviewers. There are no further outstanding issues.

Reviewer \#3: (No Response)

Reviewer \#4: All my concerns have been fully elucidated, missing sections and analyses have been completed. Finally, comprehension errors have been corrected. Good work!

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No
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If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.
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